Cellebrite (CLBT) Q3 2026 earnings review
Cellebrite lifts its profit target, but sales growth still slows
Cellebrite, which sells digital investigation software to police and governments, beat its third-quarter targets, though its fourth-quarter outlook still points to slower growth. Revenue rose 18% from a year ago, and cash profit margin jumped 6 percentage points to 36% because sales spending fell. Chief executive Shiv Ramji kept the full-year recurring contract plan unchanged while trimming full-year revenue by $2.5 million at the middle of the range.
| Recurring revenue growth, stripping acquisitions | +16.4% 20% headline growth ($528.5M) |
|---|---|
| Revenue | $149.0M +18% from a year ago (plan: $145–148M) |
| Adjusted EBITDA margin | 36.0% up 6.1 percentage points (plan: 29–30%) |
| Full-year 2026 outlook | Mixed ARR held, EBITDA raised $8.5M, revenue cut $2.5M |
⚖️ Verdict: ⚪ Neutral
The standing case is unchanged because the third-quarter rebound fixed last quarter's sales slip without raising the year-end growth trajectory. Clearing the recurring contract target and cutting sales costs eased near-term execution worries, and the company plans to move its legal parent to the United States to help win government work. The bad news: existing customer retention dipped back to 116%, the fourth-quarter revenue plan sits $5 million below what the prior outlook implied by our math, and US security regulators could still force a sale of Corellium.
The question now is whether new cloud and artificial intelligence tools like Genesis can grow fast enough to replace the fading price boost from older software upgrades. If they add new spending, year-end recurring contract growth will beat the 14–16% plan; if customers merely shift budgets between products, growth will step down into the mid-teens next year. Fourth-quarter net new recurring revenue and the initial 2027 outlook will settle it.
🐂 Bull Case
Lower Sales Spending Drove a Record Profit Margin
Cellebrite sells digital investigation software to police and government agencies, and it is squeezing much more profit from each dollar of sales. Operating profit excluding one-offs rose 43% from a year ago to $51.5 million, lifting that margin by 6.1 percentage points to 34.6%. Management raised its full-year cash profit outlook by $8.5 million at the middle of the range.
- Sales and marketing spending: 24.7% of revenue, down 6.1 percentage points from a year ago
- General and administrative overhead: 14.1% of revenue, down 1.7 percentage points
- Research and development: 24.4% of revenue, up 2.1 percentage points as the group hired engineers
- Gross margin on standard accounting: 81.2%, down 2.7 percentage points because of $5.9 million in acquisition write-offs
Finance chief David Barter said the full-year profit raise was "to reflect the outperformance from the third quarter". By our math, the new full-year target leaves fourth-quarter profit $1.6 million lower at the middle of the range than the previous plan implied, because the fourth-quarter revenue target came down.
What to watch: sales and marketing spending in the fourth quarter, when the company books its largest share of annual contracts. Holding the full-year cash profit margin near 30% would show the lower cost base is permanent.
US Federal Demand and New Certifications Advance
Sales to US government agencies and buyers of newer cloud and artificial intelligence tools are picking up after a slow start to the year. Chief executive Shiv Ramji pointed to "strong international performance, another acceleration in U.S. Federal, and Genesis gained meaningful traction in its first full quarter". Genesis is the company's new software that uses AI agents to search phone data and build investigation leads.
The software developer opened Genesis to government and corporate buyers in the United Kingdom, the European Union and Australia, and launched C-TEK, a backpack kit for military teams to extract phone data in the field. It also won a US defense cybersecurity certification, "removing a barrier to entry for federal work", and an Australian government cloud security approval for Guardian, its evidence-storage software.
What to watch: the share of new annual recurring revenue coming from newer growth products on the conference call. A reading above last quarter's 25% share would confirm that Genesis and Guardian are driving the federal rebound.
New Contract Bookings Returned to Target
"Cellebrite executed better in the third quarter, with ARR, revenue and adjusted EBITDA all finishing above our targets," Ramji said. Annual recurring revenue (ARR), the yearly value of active subscription contracts, reached $528.5 million, clearing the top of the company's $524–528 million outlook after missing its target in the second quarter.
By our math, the forensics group added $20.7 million of net new recurring revenue in the quarter, beating its $16–20 million target and edging past the $20.1 million it added a year ago. One quarter of meeting the target fades the execution concern from August, but management left the full-year recurring revenue plan unchanged.
What to watch: fourth-quarter net new recurring revenue against the $21.5–31.5 million implied by the full-year outlook. Landing in the upper half of that range would show that delayed cloud deals are closing on schedule.
🐻 Bear Case
The Fourth-Quarter Plan Still Points to Slowing Growth
Management wants investors to view Genesis as "the foundation for our next-generation platform for investigations and intelligence-led operations", but its numbers show total growth slowing down as its older software upgrade cycle matures. Headline recurring revenue grew 20% from a year ago, or 16.4% by our math when stripping out the $16.6 million bought with Corellium and SCG Canada at closing.
- Net retention rate (spending by existing customers vs a year ago): 116%, down from 117% last quarter and 124% seven quarters ago
- Full-year recurring revenue outlook: held at $550–560 million, or 14–16% growth as the Corellium purchase passes its one-year mark
- Fourth-quarter revenue outlook: $145–150 million, which is $4.6 million below what the prior full-year plan implied by our math
Barter said the company is "reaffirming our full-year 2026 ARR outlook while fine-tuning this year’s revenue targets to reflect more ratable revenue from cloud and AI and less hardware revenue compared with the third quarter". Cloud contracts spread revenue over time rather than booking it up front, but keeping the recurring contract target unchanged means new AI sales are not yet outrunning the slowdown in older products.
What to watch: the net retention rate and the initial 2027 growth outlook next quarter. A retention rate below 115% would confirm that customer upgrades are slowing faster than new cloud tools can replace them.
US Security Review Threatens the Corellium Deal
Cellebrite bought Corellium, a maker of virtual phone software used for security testing, in December 2025 for about $150 million in cash plus stock. The purchase still lacks clearance from the Committee on Foreign Investment in the United States (CFIUS), the federal panel that reviews foreign takeovers for national security risks.
In a new warning in the release, the Israeli company said it is "seeking to address CFIUS’ concerns in lieu of potential divestment" and cannot predict the outcome. Corellium brought $16.1 million of annual recurring revenue at closing — about 3 percentage points of this year's growth — and sits inside the Autumn product release, so a forced sale would strip out revenue and disrupt its engineering plans.
What to watch: a final binding decision from the US security panel or a mitigation agreement. A forced sale would remove Corellium's recurring contracts from the 2027 growth base.
Risks this quarter didn't answer
Several standing concerns from prior quarters received no new figures in the third-quarter press release or remained unresolved.
- Unbilled contract backlog: total and unbilled remaining performance obligations fell in the first half and were not reported in the release; the conference call or filing will show if multi-year bookings recovered.
- Dollar revenue from new AI and cloud products: management cited traction for Genesis without disclosing its dollar recurring revenue; the call remarks are the place to check.
- Gap between standard and adjusted profit: employee stock pay ($15.4 million) and acquisition write-offs ($7.2 million) consumed 44% of adjusted operating profit, while diluted shares rose 1.9% from a year ago with no share buybacks.
- Long-term targets and ownership: the release did not mention the old $1 billion revenue goal, the Israeli shekel's cost impact, or Sun Corporation's roughly 40% shareholding, while adding a new strategy chief and a new research lab head after recent executive turnover.
👓 Other Themes
Plans to Move Legal Home to the US
In mid-September, Cellebrite announced a plan for "establishing a new United States corporation as the ultimate parent company", subject to shareholder and regulatory approvals. Management expects moving its legal home from Israel to the US to support "growth in its largest geographic market and with other large government customers outside of the U.S.", where foreign-entity permit rules have slowed cloud contracts, and to qualify the stock for US market indices.
💲 Other KPIs
Free cash flow — operating cash after equipment and software spending — rose 73% from a year ago to $51.8 million, or 34.8% of revenue. Over the last twelve months, cash flow reached $166.0 million, lifting the twelve-month margin to 30.9% from 28.0% last quarter and putting the full-year 30% target within reach.
Deferred revenue — cash billed to customers for software services not yet delivered — rose 22.0% from a year ago by our math ($295.5 million current plus $51.1 million long-term), outpacing 18.2% revenue growth after lagging in the second quarter. Trade receivables — bills customers have not yet paid — also climbed $29.1 million in the quarter to $139.8 million.
Cash, short-term deposits and marketable securities rose by $47.6 million from June to $593.3 million by our math, and the digital forensics provider continues to carry no bank debt. The company spent $8.5 million on intangible assets and $4.8 million on capital equipment during the quarter, with no share repurchases.
🔮 Guidance
Unchanged. The plan keeps year-end recurring contract growth at 14–16% (15.4% at the middle of the range), down from 20.2% in the third quarter. By our math, that leaves $21.5–31.5 million of net new recurring revenue for the fourth quarter ($26.5 million at the middle), about 6% above last year's fourth-quarter addition once the $16.1 million bought with Corellium is stripped out.
Cut. Management trimmed the full-year sales range by $2.5 million at the middle, to 16.8% growth, after cutting it by $10 million last quarter. Barter blamed a shift toward cloud and AI subscriptions that recognize revenue gradually over the contract rather than up front like hardware.
Cut against what the prior full-year plan implied. The fourth-quarter outlook calls for 13–16% growth from a year ago (14.5% at the middle) and a 1% drop from the third quarter. By our math, the middle of the range sits $4.6 million below the $152.1 million that last quarter's full-year target left for the fourth quarter.
Raised. The middle of the cash profit range moved up $8.5 million to $164.5 million (a 29–30% margin), following a $4.0 million raise last quarter. The entire increase came from the $10.1 million third-quarter beat.
Trimmed slightly against the prior implied remainder. The plan puts fourth-quarter cash profit margin at 32–33%, down from 36.0% in the third quarter, and sits $1.6 million below what the prior full-year plan implied at the middle of the range. If its three-quarter average beat of 14.2% holds, fourth-quarter profit would land near $55.4 million by our math.
Unchanged. Management still expects free cash flow to equal about 30% of revenue for the full year. With $83.2 million collected in the first nine months, the target requires about $83.5 million in the fourth quarter by our math, in line with the $82.9 million collected in last year's fourth quarter.
❓ Key Questions
What are the US security panel's concerns over Corellium?
The release warns that Cellebrite is trying to address CFIUS concerns instead of a potential forced sale of Corellium. Investors need to know whether the panel is asking for operational walls or if a forced divestment of that $16 million revenue stream is a real risk.
How much recurring revenue do Genesis and growth products generate?
Management said Genesis gained meaningful traction in its first full quarter, but the release gave no dollar figure or share of new bookings. Without that number, investors cannot tell if AI tools can offset the maturing Inseyets upgrade cycle.
Did unbilled contract backlog recover in the third quarter?
Unbilled remaining performance obligations fell 27% in the first half of the year and did not appear in the press release. The third-quarter reading will show whether customers are signing multi-year contracts again or shifting to shorter commitments.
How will moving the parent company to the US work?
Cellebrite plans to set up a US parent company to ease government sales and enter US stock indices. Management has not yet detailed the timeline, the tax cost in Israel, or whether the move resolves foreign-entity permit delays.